ICLE 2022 | Testing viral vectors for CAR therapies with in vivo models
Alexander Michels
• 1 Apr 2022
Alexander Michels, Paul-Ehrlich-Institut, Langen, Germany, describes research on advanced viral vectors for the testing of chimeric antigen receptor (CAR)-T cell therapies and gene therapies. Adeno-associated viral (AAV) and lentiviral vectors were engineered to target CD8 in syngeneic mouse models with a DARPin found via a ribosome display and subsequently inserted in the entry machinery of the vectors. Both investigational vectors were found to be highly selective for CD8 presenting cells and have the potential to target multiple murine receptors. Future lines of research include assessing the vectors in in vivo models. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
